Kymera Investor Day Presentation Deck
KT-474 Demonstrates Broadest Anti-inflammatory Effect Compared
to Other Clinical Agents
Agent/Stimulus Target IFNY
IRAK4
(degrader)
✓
✓
KT-474/LPS
KT-474/R848
CA-4948/R848
GS-5718/R848
ATI-450/LPS
ATI-450/IL-13
LY2775240/LPS
Iberdomide/LPS
JNJ-61803534/
T cell activation
Inhibition of Ex Vivo Disease Relevant Cytokine/Chemokine Stimulation
by Anti-Inflammatory Agents in Ph1 Studies
TNFa IL-1B
IL-6
IL-8
IL-17
✓
✓
* Non-selective
IRAK4
(degrader)
IRAK4*
(inhibitor)
IRAK4
(inhibitor)
MK2
MK2
PDE4
Ikaros/
Aiolos
RORY
✓
✓
KYMERA ©2021 KYMERA THERAPEUTICS, INC.
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
IL-12
✓
✓
IL-23
✓
IL-10
✓
Iberdomide: Schafer PH, et al. Ann Rheum Dis 2018;77:1516-1523; LY2775240: Patel DR, et al. Clin Transl Sci. 2021;14:1037-1048; JNJ61803534: Xue X, et al. Sci Rep 2021;11:11066-
80; MK2: Aclaris 2021 Company Overview; CA-4948: Booher RN, et al. ASH Annual Meeting 2018, Poster #4168; GS-5718: Roedder S, et al. ACR Convergence 2021, Poster #0185
KYMERA R&D DAY - December 16th, 2021
PAGE 31View entire presentation